Forum Financier de Charleroi. 18 novembre 2014

Transcription

1 Forum Financier de Charleroi 18 novembre 2014 Dominique Demonté, Ph.D. Director of the BIOPARK Member of the Board of BioWin President of SPOW

2 Life sciences in Wallonia Innovative life science companies Major investments in Life Sciences - Private investments in R&D: 1,5 billion/year - Public investments in R&D: 165 Mio/year direct jobs World leaders Unique Business Vaccines Total staff (Belgium) 7,200 R&D >2,300 (30%) Immunology/CNS Total staff (Belgium) 2,000 R&D 720 (36%) Diagnostic and Cancer Therapy Total staff (Belgium) 380 R&D 90 (30%) Medical devices/ biopharmaceuticals Total staff (Belgium) 2,000 R&D 200 (10%) and many innovative SMEs

3 Life sciences in Wallonia High level universities 16 research centers dedicated to life sciences Unique Science - Ludwig Institute for Cancer Research - GIGA («omics» technologies) - Institute for Medical Immunology - Institute of Cellular and Molecular Pathology (De Duve) - Center for Microscopy and Molecular Imaging (CMMI) - CER Groupe and ImmuneHealth - European leader in clinicals trials 7 major university hospitals (10,000 beds) 20% of 73,0000 students in life sciences 670 PhDs in biomed sciences

4 Life sciences in Wallonia A strategy and a strong culture of Public-Private Partnerships

5 SPoW : SCIENCE PARKS OF WALLONIA 1. Management by Regional development agencies & universities 2. High Tech Companies, research centers and specific infrastructures 3. Technology Transfer & Networking activities Companies ~ Spin-offs 73 - Big cp 20% - Foreign cp 20% People ~ 13,000 Network of 7 science and technology parks located in Wallonia.

6 The BIOPARK Charleroi ULB s Biomedical Campus in CHARLEROI First research institute created in research institutes and 32 companies 900 jobs 17 nationalities

7 Companies Research The complete innovation chain Incubation-Valorisation Training

8 Institute for Molecular Biology and Medicine Founded in 1999 by ULB, Wallonia and the EU with 2 objectives Strengthen our expertise in molecular biology Play an active role in the development of Charleroi Today : 180 persons working on three main research topics Functional genetic Cell biology and imaging Host/parasite relationships

9 Institute for Medical Immunology 50% 25% Created In 2004 on the basis of a PPP between GSK-Biologicals, Wallonia and ULB 65 members working on three main research topics : 25% Vaccinology : Mode of action of adjuvants and role of innate immune response in shaping adaptive immune responses Neonatal Immunology : Human response to congenital CMV infection Transplantation: Immune suppression and tolerance

10 Center for Microscopy and Molecular Imaging Created by ULB and UMONS with the support of EU and Wallonia Preclinical imaging platform dedicated to Research and Services 8 associates laboratories from faculties of Science, Medicine & Engineering Organized in 4 departments Microscopy Immunohistochemistry In vivo imaging Multimodal image processing

11 Functional imaging : from molecule to small animal Molecules Cellular Compartments Cells Cellular populations Tissues Small animal

12

13 Improve the competitiveness of the campus and promote collaborations Collaborations with Companies, IP, ACADEMIC RESEARCHES Support for Spinoffs creation, Funds raising COMPANIES Training of Students and scientists

14 The Technology Transfer Process Research Technology Transfer Incubation Funding Value Creation 3 scientific advisers and 1 economist Specialized in life science Contacts with companies, IP management, patents, Economic evaluation of the projects Strategy and Business plan Fund raising Investment in projects, follow up Exit strategy,...

15 The missions : support the creation, development and attraction of High Tech companies

16

17 Plus de 5 0 partenaires collaborent au sein de not re écosystèm e, au service des proj ets accom pagnés Universités et centres de recherche Acteurs publics Acteurs financiers privés Entreprises privées A-ULaB

18 13 ULB Spin-offs have been created since new companies on the campus since attraction of 2 foreign companies : ORGENESIS (Israël) and PLURIOMICS (the Netherlands) 32 companies

19

20

21 Training sessions for academic teachers to reduce competence gaps and for a be er match between the ini al curriculum and the needs of the biomed sector elearning classroom-training

22 Short and intensive programs for the workers (eg, scien sts, technologists, managers and industrialists) Science & technology Intensive MBA for biomedical execu ves On-line or/and face-to-face courses & prac cal hands-on training

23

24 Created in ,870 enterprises Total investment worth $25.08 billion Should be in 2017.

25 Intégration du Biopark dans le réseau économique Wallon Ville de Charleroi Commission prospective Charleroi Comité de Développement Stratégique Chef de grappe Biotech Entreprises Ecoles/hautes écoles Acteurs Economiques BioWin (conseil de gouvernance) SPOW (présidence) WBC (conseil d administration) ACCORD (conseil d administration) IRE (conseil d administration) Pôle Hainuyer (conseil d administration) B4C (conseil d administration) Future Agence de l Entreprise et de l innovation (conseil d administration)

26 Une stratégie de communication adaptée Régional Nous sommes un pôle de recherche et de développement économique Wallon Outils de communication (newsletter BIOPARK, site Web, Tweeter, Linked in,...) Présentations du Biopark (banques, clubs entreprises, politiques, écoles,...) Identité forte du BIOPARK (Région, politiques, autres universités et international) Très bonne présence dans les médias (scientifiques et économiques) Bonne image au niveau de la région et de la commission européenne Presse :Le soir, Trends, l Echo, l Avenir, Télévision et radio : RTBF, RTL, télésambre, vidéo campagne plus haut,...

27 Développer des écosystèmes Innovants Smart Specialisation Choix de thématiques avec des masses critiques suffisantes sur le Biopark et en FWB Immunologie Imagerie Thérapie cellulaire et... Une stratégie intégrée...

28 Une stratégie de communication et des actions adaptées International Pôle attractif pour les chercheurs et des entreprises en : Immunologie, Imagerie et Thérapie cellulaire Outils de communication (Brochure BIOPARK, site Web, Linked in,...) Présentation du Biopark (Délégations internationales, AWEX, Ambassadeurs, EEN, sociétés étrangères,...) Missions BioWin spécifiques (Lyon, Nantes, San Diego,...) et liens avec Biopark étrangers (Pologne, Inde) Organisation B4B connection Immunologie en Mai 2014 (160 personnes)

29 Développement d une stratégie de création et d attraction d entreprises Research Companies Training International Network Specific Hunting! Research institutes and companies are developing tools (Flow cytometry, in vivo cell tracking, immunogenicity) Belgium is an European leader : first cell therapy product approved in Europe (TiGenix) Largest manufacturing capacities for cell therapy in Europe will be on the Biopark To support the sector we have developed specific training programs Highly skilled scientists supported by specific training program

30 Développement d une stratégie de création et d attraction d entreprises Production pour tiers International Network Specific Hunting! Développement de la cytométrie de Flux pour le QC et de test pour cellule Développement de formation pour le personnel Développement d outils d imagerie pour le suivi des cellules in Vivo

31 The Biopark : Research and business ecosystem dedicated to Immunology Research Preclinical developments Production Clinical Immunomonitoring Development of new products

32 Wallonia is also an ecosystem dedicated to Immunology International Network High level of research Headquarters of GSK Vaccines (staff 8000, 30 % in R&D) and UCB International network and collaborations with SANOFI, NOVARTIS, Highly skilled scientists supported by specific training program Creation and attraction of new SMEs... Specific Hunting!

33 An ecosystem dedicated to Imaging Research Companies Training International Network 8 modules 300 participants since 2012 Major players in the field IBA, IRE, The highest worldwide level of development in nuclear medicine and applications of radioactivity in healthcare (diagnostic, therapy, ) A very high density of equipment (cyclotrons, cameras) One of the largest numbers of experts in this domain (university and industry)

34 Biopark, le futur BIOPARK Charleroi Brussels South

35 1. Renforcer le cluster Thérapie cellulaire Attracting companies in Imaging, Immunology and Cell therapy International Network

36 2. Développer les collaborations avec les hôpitaux de la FWB Centre de Protonthérapie Localisé à côté du nouvel Hôpital Marie-Curie Etudes précliniques Nouveaux traceurs d imagerie Patients étrangers

37 ITECH SUPPORT et Valorisateurs 3. Renforcer le potentiel de Recherche et l écosystème dans les axes stratégiques Thérapie cellulaire Imagerie Immunothérapies BATIMENT NOVALIS 2 Bioprofiling Immunologie Diagnos c-biomarqueurs Imagerie Human Biological Samples FORMATION BATIMENT ITECH INCUBATOR 3 Portefeuille Wallonia-Biomed FEDER-FSE

38 Conclusions... Le BIOPARK est un pôle de Recherches et de Développements économiques Nous disposons de tous les outils pour son développement L articulation des activités et la constitution de masses critiques sont essentielles pour sa croissance Un soutien public reste crucial pour maintenir la dynamique La non-linéarité entre les résultats de la Recherche et les développements industriels est un fait à intégrer dans les stratégies de développement régional Ceci doit être compensé par le renforcement d écosystèmes intégrés et innovants au sein desquels Recherche, Formation et Développements Industriels se renforcent mutuellement

39 Dominique Demonté, Ph.D. Director of the BIOPARK